Drug Profile
Research programme: AMPK activators - Betagenon/iNovacia
Alternative Names: BG 8702; BG800 compounds; BG800 projectLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Betagenon
- Class Small molecules
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Sweden (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in United Kingdom (PO)
- 15 Sep 2008 Betagenon and iNovacia agree to collaborate in the discovery and optimisation of Betagenon's compounds in Sweden